期刊档案 · Multiple
Vaccine: X
ISSN 2590-1362 · Elsevier · United Kingdom
Vaccine: X 中科院 医学 4区（2025 年升级版），影响因子 2.5（官网公布），完全开放获取，APC 约 2,520 美元，近 24 个月 34 篇文章投稿到接收中位 155 天，2025 年发文 158 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
Vaccine: X 由 Elsevier 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Vaccine Coverage and Hesitancy、SARS-CoV-2 and COVID-19 Research、Influenza Virus Research Studies 等主题的论文，这 3 个主题约占 43.6%，主导子领域为 Epidemiology。（根据 OpenAlex 主题统计与中科院分区数据生成）
Vaccine: X is the open access companion journal of Vaccine and has the same aims and scope. The journal offers authors who want to publish in a gold open access journal the opportunity to make their work immediately and permanently accessible.Vaccine: X publishes high quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas (such as passive immunization) are welcomed. Relevant, sound scientific work in all aspects of vaccine research that yielded negative results and would otherwise not be published is also welcome. Besides original research, we invite authors to submit basic science and clinical reviews, methodological articles, case reports, opinion and commentary pieces, visual pieces, and letters. Authors are required to consult the Guide for Authors as the submission guidelines are dynamic and therefore subject to change.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Multiple
主编 Richard B. Kennedy出版商官网
编委会国家分布：中国大陆 1 位（约 3%）；主要国家 美国 11、澳大利亚 5、意大利 4、英国 2、荷兰 2（共 33 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Vaccine Coverage and HesitancySocial Sciences23.4%
- SARS-CoV-2 and COVID-19 ResearchMedicine12.5%
- Influenza Virus Research StudiesMedicine7.6%
- Respiratory viral infections researchMedicine5.4%
- Immune responses and vaccinationsImmunology and Microbiology5.2%
- COVID-19 epidemiological studiesMathematics3.7%
- Cervical Cancer and HPV ResearchMedicine3.5%
- Virology and Viral DiseasesMedicine3.4%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 免疫学IMMUNOLOGY | 4 区 |
| 小类 | 医学：研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 免疫学IMMUNOLOGY | 3 区 |
| 小类 | 医学：研究与实验MEDICINE, RESEARCH & EXPERIMENTAL | 3 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布）
- 2.5出版商官网 ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore（出版商公布）
- 4.2出版商官网 ·
- SJR 2026-06
- 0.7LetPub ·
- SNIP 2026-06
- 0.73LetPub ·
- h-index
- 34OpenAlex ·
- i10-index
- 190OpenAlex ·
- 两年平均被引
- 2.5OpenAlex ·
- 自引率
- 4%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 129LetPub ·
逐年发文量 OpenAlex 统计 · 累计 850 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 127 | 127 | 18 |
| 2025 | 158 | 158 | 162 |
| 2024 | 169 | 169 | 955 |
| 2023 | 163 | 163 | 1,197 |
| 2022 | 115 | 115 | 1,418 |
| 2021 | 50 | 50 | 923 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
155 天投稿到接收中位数 · P25–P75 110 天 – 241 天
- 接收到上线
- 中位数 3 天（33 篇）
- 投稿到上线
- 中位数 156 天
- 样本
- 34 篇有投稿与接收日期的文章（窗口内共 52 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 13 WeeksLetPub ·
- 投稿到首次决定
- 7 天出版商官网 ·
- 外审后首次决定
- 79 天出版商官网 ·
- 投稿到接收
- 134 天出版商官网 ·
- 接收到发表
- 3 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 13 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,520 | 有 | CC BY、CC BY-NC、CC BY-NC-ND | |
| OpenAlex | USD 2,440 / EUR 2,280 / GBP 1,950 / JPY 302,630 | — | — | |
| LetPub | USD 2,000 | 有 | — | |
| 出版商官网 | USD 2,550 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点6 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 1–7 个
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- Highlights（研究亮点）
- 可选
- 图文摘要
- 可选
- 投稿信（Cover letter）
- 必须提供
接收的文章类型17 种
- case reportVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- case reportsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.未说明篇幅
- commentariesVaccine: X also welcomes thoughtful Opinion Pieces and Commentaries on topics of interest to the readership of the journal.未说明篇幅
- commentaryVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- conference reportVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- conference reportsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.未说明篇幅
- letterVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- letters to the editorsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.未说明篇幅
- opinionVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- opinion piecesVaccine: X also welcomes thoughtful Opinion Pieces and Commentaries on topics of interest to the readership of the journal.未说明篇幅
- research paperVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- research papersVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.未说明篇幅
- reviewVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- review articleVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- review articlesVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.未说明篇幅
- short communicationVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.Vaccine: X also…未说明篇幅
- short communicationsVaccine: X publishes primary Research Papers, Review Articles, Short Communications, Conference Reports, Case Reports and Letters to the editors.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 数据可用性
Data statement required at submission 模型摘要
To foster transparency, you are required to state the availability of any data at submission.
原文 ↗出版商官网 ·- 许可与版权 License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
Single anonymized review process 模型摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
Preprint sharing allowed, does not count as prior publication 模型摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 2590-1362
- 学会 / 主办单位
- Japanese Society for Vaccinology
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Vaccine: X 的常见问题
Vaccine: X 是中科院几区期刊？
2025 年升级版分区表中，Vaccine: X 为医学 4区，小类 免疫学 / 医学：研究与实验 4 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Vaccine: X 的影响因子是多少？
期刊官网公布的影响因子为 2.5，属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 4.2，h-index 为 34。
Vaccine: X 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）34 篇已发表文章登记的日期，投稿到接收的中位数为 155 天（四分位 110–241 天）；投稿社区反馈的平均审稿速度为约 13 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Vaccine: X 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：1–7 个；参考文献格式：顺序编码制（按引用顺序编号）；Highlights：可选；图文摘要：可选；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Vaccine: X 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 33 位编委中，中国大陆 1 位（约 3%）；人数最多的国家是 美国（11 位）、澳大利亚（5 位）、意大利（4 位）。统计按编委会页面列出的机构国家计，仅供参考。
Vaccine: X 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Vaccine: X 被 ESCI、Scopus、DOAJ 收录。
Vaccine: X 是开放获取期刊吗？版面费多少？
Vaccine: X 为完全开放获取。APC 约 2,520 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。